Treatments

Drug Calms Overly Excitable Brains in Autism Rodent Models

Source: 
Simons Foundation Autism Research Initiative
Date Published: 
February 10, 2014
Abstract: 

The blood pressure drug bumetanide normalizes a deficit in brain activity in two rodent models of autism, according to a study published in Science. The study hints at a mechanism underlying the drug’s benefits for people with autism. Neurochlore, a company based in Marseilles, France, is testing bumetanide as a treatment for autism. In the first phase, 27 children with autism showed some improvement in their autism symptoms; the researchers are continuing the trial in Europe with more participants.

Young Children With Autism Benefit Regardless of High-Quality Treatment Model

Source: 
Journal of Autism and Developmental Disorders
Date Published: 
June 28, 2013
Abstract: 

A UNC comparative efficacy study that compared the LEAP, TEACCH and Non-Model-Specific Special Education Programs found that young children who receive high-quality early intervention benefit developmentally regardless of the treatment model used.

Arboclofen Has Potential to Improve Social Function and Behavior in Patients with Fragile X Syndrome

Source: 
Science Translational Medicine
Date Published: 
September 9, 2012
Abstract: 

Research on animal models suggests that STX209 (arboclofen) might improve neurobehavioral function in patients affected with Fragile X Syndrome.

Seaside Therapeutics Discontinues Arbaclofen (STX209) Extension Study

Source: 
The Boston Globe
Date Published: 
May 31, 2013
Abstract: 

Seaside Therapeutics has discontinued their extension study of Arbaclofen (STX209), a drug that showed promise in treating social impairment related to Fragile X syndrome.

How Can Immigrant Families Get Help For Their Autistic Child

Source: 
ASF Blog
Date Published: 
May 24, 2013
Abstract: 

Guest blogger Marcela De Vivo shares insight on some of the difficulties immigrant families face when getting help for their child with autism in this week's ASF blog post.

Environmental Enrichment as an Effective Treatment for Autism: A Randomized Controlled Trial

Source: 
Behavioral Neuroscience
Date Published: 
May 20, 2013
Abstract: 

Researchers at University of California Irvine conducted a randomized controlled trial of sensorimotor enrichment in young boys with ASD. Behavioral and cognitive improvements in the children who received sensorimotor therapy suggest that it may be a promising treatment for ASD symptoms. The group is now conducting a larger trial that includes girls.

Cognitive Enhancement Therapy for Adults with Autism Spectrum Disorder: Results of an 18-month Feasibility Study

Source: 
Journal of Autism and Developmental Disorders
Date Published: 
April 26, 2013
Abstract: 

New findings from a small pilot study suggest cognitive enhancement therapy is a feasible and effective intervention for cognitive impairments in verbal adults with ASD. Adult participants were highly satisfied with the therapy and treatment attendance was high, indicating their willingness to participate in and commit to an intervention that they considered useful.

Brief Report: Is Cognitive Rehabilitation Needed in Verbal Adults with Autism? Insights from Initial Enrollment in a Trial of Cognitive Enhancement Therapy

Source: 
Journal of Autism and Developmental Disorders
Date Published: 
February 5, 2013
Abstract: 

Early results from this pilot trial of cognitive enhancement therapy (CET) indicate that despite above-average intelligence, verbal adults with ASD can have significantly impaired neurocognition and social cognition. The authors suggest CET, which is designed to remediate both social and non-social deficits through computer-based neurocognitive training, could be useful for cognitive rehabilitation in this population.